Molecular pathology of lung cancer: clinical aspects
Abstract
About the Authors
I. S. PolyakovRussian Federation
E. N. Imyanitov
Russian Federation
References
1. Alexandrov L.B., Nik-Zainal S., Wedge D.C. et al. Signatures of mutational processes in human cancer//Nature. 2013. Vol. 500 (7463). P. 415-421
2. Bauml J., Mick R., Zhang Y. et al. Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist?//Lung Cancer. 2013. Vol. 81. P. 347-353
3. Boch C., Kollmeier J., Roth A. et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study//BMJ Open. 2013. Vol. 3. P. e002560
4. Bos M., Gardizi M., Schildhaus H.U. et al. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib//Lung Cancer. 2013. Vol. 81. P. 142-143
5. Burton A. What went wrong with Iressa?//Lancet Oncol. 2002. Vol. 3. P. 708
6. Camidge D.R., Bang Y.J., Kwak E.L. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study//Lancet Oncol. 2012. Vol. 13. P. 1011-1019
7. Cancer GenomeAtlas ResearchNetwork.Comprehensivegenomic characterization of squamous cell lung cancers//Nature. 2012. Vol. 489. P. 519-525
8. Cohen M.H., Williams G.A., Sridhara R. et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets//Oncologist. 2003. Vol. 8. P. 303-306
9. D’Angelo S.P., Janjigian Y.Y., Ahye N. et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib//J. Thorac. Oncol. 2012. Vol. 7. P. 1815-1822
10. D’Arcangelo M., Wynes M.W., Hirsch F.R. et al. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer//Curr. Opin. Oncol. 2013. Vol. 25. P. 121-129
11. Ding L., Getz G., Wheeler D.A. et al. Somatic mutations affect key pathways in lung adenocarcinoma//Nature. 2008. Vol. 455. P. 1069-1075
12. Doebele R.C., Pilling A.B., Aisner D.L. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer//Clin. Cancer Res. 2012. Vol. 18. P. 1472-1482
13. Drilon A., Rekhtman N., Ladanyi M., Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy//Lancet Oncol. 2012. Vol. 13. E. 418-426
14. Fukui T., Yatabe Y., Kobayashi Y. et al. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene//Lung Cancer. 2012. Vol. 77. P. 319-325
15. Fukuoka M., Wu Y.L., Thongprasert S. et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)//J. Clin. Oncol. 2011. Vol. 29. P. 2866-2874
16. Garraway L.A., Lander E.S. Lessons from the cancer genome//Cell. 2013. Vol. 153. P. 17-37
17. Gautschi O., Pauli C., Strobel K. et al. Apatient with BRAF V600E lung adenocarcinoma responding to vemurafenib//J. Thorac. Oncol. 2012. Vol. 7. P. e23-e24
18. Giaccone G., Herbst R.S., Manegold C. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1//J. Clin. Oncol. 2004. Vol. 22. P. 777-784
19. Goto K., Nishio M., Yamamoto N. et al. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)//Lung Cancer. 2013. Vol. 82 (1). P. 109-114
20. Govindan R., Ding L., Griffith M. et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers//Cell. 2012. Vol. 150. P. 1121-1134
21. Herbst R.S., Giaccone G., Schiller J.H. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2//J. Clin. Oncol. 2004. Vol. 22. P. 785-794
22. Imielinski M., Berger A.H., Hammerman P.S. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing//Cell. 2012. Vol. 150. P. 1107-1120
23. Inoue A., Kobayashi K., Maemondo M. et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)//Ann. Oncol. 2013. Vol. 24. P. 54-59
24. Jakobsen J.N., Sørensen J.B. Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer//Cancer. Chemother. Pharmacol. 2012. Vol. 69. P. 289-299
25. Jänne P.A., Shaw A.T., Pereira J.R. et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study//Lancet Oncol. 2013. Vol. 14. P. 38-47
26. Katakami N., Atagi S., Goto K. et al. LUX-Lung 4: A phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both//J. Clin. Oncol. 2013 (in press)
27. Komiya T., Thomas A., Khozin S. et al. Response to crizotinib in ROS1-rearranged non-small-cell lung cancer//J. Clin. Oncol. 2012. Vol. 30. P. 3425-3426
28. Ku G.Y., Haaland B.A., de Lima Lopes G. Jr. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: metaanalysis of phase III trials//Lung Cancer. 2011. Vol. 74. P. 469-473
29. Kwak E.L., Bang Y.J., Camidge D.R. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer//N. Engl. J. Med. 2010. Vol. 363. P. 1693-1703
30. Levchenko E.V., Moiseyenko V.M., Matsko D.E. et al. Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases//Onkologie. 2009. Vol. 32. P. 674-677
31. Liao R.G., Jung J., Tchaicha J. et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma//Cancer Res. 2013. Vol. 73. P. 5195-5205
32. Lim S.M., Kim H.R., Shim H.S. et al. Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma//Future Oncol. 2013. Vol. 9. P. 377-386
33. Lindeman N.I., Cagle P.T., Beasley M.B. et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology//J. Thorac. Oncol. 2013. Vol. 8. P. 823-859
34. Lipson D., Capelletti M., Yelensky R. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies//Nat. Med. 2012. Vol. 18. P. 382-384
35. Lynch T.J., Bell D.W., Sordella R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib//N. Engl. J. Med. 2004. Vol. 350. P. 2129-2139
36. Maemondo M., Inoue A., Kobayashi K. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR//N. Engl. J. Med. 2010. Vol. 362. P. 2380-2388
37. Marchetti A., Felicioni L., Malatesta S. et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations//J. Clin. Oncol. 2011. Vol. 29. P. 3574-3579
38. Mattsson J.S., Imgenberg-Kreuz J., Edlund K. et al. Consistent mutation status within histologically heterogeneous lung cancer lesions//Histopathology. 2012. Vol. 61. P. 744-748
39. Mazières J., Peters S., Lepage B. et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives//J. Clin. Oncol. 2013. Vol. 31. P. 1997-2003
40. Miller V.A., Hirsh V., Cadranel J. et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1P.) a phase 2b/3 randomised trial//Lancet Oncol. 2012. Vol. 13. P. 528-538
41. Mitiushkina N.V., Iyevleva A.G., Poltoratskiy A.N. et al. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides//Cancer Cytopathol. 2013. Vol. 121. P. 370-376
42. Mitsudomi T., Morita S., Yatabe Y. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405P.) an open label, randomised phase 3 trial//Lancet Oncol. 2010. Vol. 11. P. 121-128
43. Moiseyenko V.M., Procenko S.A., Levchenko E.V. et al. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma//Onkologie. 2010. Vol. 33. P. 231-238
44. Mok T.S., Wu Y.L., Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma//N. Engl. J. Med. 2009. Vol. 361. P. 947-957
45. Murakami Y., Mitsudomi T., Yatabe Y. A Screening Method for the ALK Fusion Gene in NSCLC//Front Oncol. 2012. Vol. 2. P. 24
46. Nagashima O., Ohashi R., Yoshioka Y. et al. High prevalence of gene abnormalities in young patients with lung cancer//J. Thorac. Dis. 2013. Vol. 5. P. 27-30
47. Nurwidya F., Murakami A., Takahashi F., Takahashi K. Molecular mechanisms contributing to resistance to tyrosine kinase-targeted therapy for non-small cell lung cancer//Cancer Biol. Med. 2012. Vol. 9. P. 18-22
48. Oh I.J., Ban H.J., Kim K.S. et al. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study//Lung Cancer. 2012. Vol. 77. P. 121-127
49. Oxnard G.R., Miller V.A., Robson M.E. et al. Screening for germ-line EGFR T790M mutations through lung cancer genotyping//J. Thorac. Oncol. 2012. Vol. 7. P. 1049-1052
50. Paez J.G., Jänne P.A., Lee J.C. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy//Science. 2004. Vol. 304. P. 1497-1500
51. Pao W., Girard N. New driver mutations in non-small-cell lung cancer//Lancet Oncol. 2011. Vol. 12. P. 175-180
52. Pao W., Miller V., Zakowski M. et al. EGF receptor gene mutations are common in lung cancers from „never smokers“ and are associated with sensitivity of tumors to gefitinib and erlotinib//Proc. Natl. Acad. Sci. USA. 2004. Vol. 101. P. 13306-13311
53. Pillai R.N., Ramalingam S.S. The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation//Curr. Oncol. Rep. 2012. Vol. 14. P. 105-110
54. Pleasance E.D., Stephens P.J., O’Meara S. et al. A small-cell lung cancer genome with complex signatures of tobacco exposure//Nature. 2010. Vol. 463. P. 184-190
55. Ranson M., Hammond L.A., Ferry D. et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial//J. Clin. Oncol. 2002. Vol. 20. P. 2240-2250
56. Rikova K., Guo A., Zeng Q. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer//Cell. 2007. Vol. 131. P. 1190-1203
57. Rosell R., Moran T., Queralt C. et al. Screening for epidermal growth factor receptor mutations in lung cancer//N. Engl. J. Med. 2009. Vol. 361. P. 958-967
58. Seto T., Kiura K., Nishio M. et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF001JP study): a single-arm, open-label, phase 1-2 study//Lancet Oncol. 2013. Vol. 14. P. 590-598
59. Sequist L.V., Yang J.C., Yamamoto N. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations//J. Clin. Oncol. 2013. Vol. 31 (27). P. 3327-3334
60. Shaw A.T., Engelman J.A. ALK in lung cancer: past, present, and future//J. Clin. Oncol. 2013. Vol. 31. P. 1105-1111
61. Shaw A.T., Kim D.W., Nakagawa K. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer//N. Engl. J. Med. 2013. Vol. 368. P. 2385-2394
62. Shaw A.T., Yeap B.Y., Solomon B.J. et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis//Lancet Oncol. 2011. Vol. 12. P. 1004-1012
63. Shigematsu H., Lin L., Takahashi T. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers//J. Natl. Cancer Inst. 2005. Vol. 97. P. 339-346
64. Soda M., Choi Y.L., Enomoto M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer//Nature. 2007. Vol. 448. P. 561-566
65. Suspitsin E.N., Levchenko E.V., Moiseyenko F.V. et al. Rapid symptomatic improvement in gefitinib-treated patients with EGFR-mutated lung cancer: possible role of downregulation of inflammatory molecules?//Onkologie. 2011. Vol. 34. P. 559-560
66. Takahashi R., Hirata H., Tachibana I. et al. Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung//Clin. Cancer Res. 2012. Vol. 18. P. 220-228
67. Takeuchi K., Soda M., Togashi Y. et al. RET, ROS1 and ALK fusions in lung cancer//Nat. Med. 2012. Vol. 18. P. 378-381
68. Tanizaki J., Okamoto I., Okabe T. et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer//Clin. Cancer Res. 2012. Vol. 18. P. 6219-6226
69. Thunnissen E., Bubendorf L., Dietel M. et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations//Virchows Arch. 2012. Vol. 461. P. 245-257
70. van Noesel J., van der Ven W.H., van Os T.A. et al. Activatinggermline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation//J. Clin. Oncol. 2013. Vol. 31. E. 161-164
71. Wang R., Pan Y., Li C. et al. The use of quantitative real-time reverse transcriptase PCR for 5‘ and 3‘ portions of ALK transcripts to detect ALK rearrangements in lung cancers//Clin Cancer Res. 2012. Vol. 18. P. 4725-4732
72. Yu H.A., Arcila M.E., Rekhtman N. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers//Clin. Cancer Res. 2013. Vol. 19. P. 2240-2247
Review
For citations:
Polyakov I.S., Imyanitov E.N. Molecular pathology of lung cancer: clinical aspects. Siberian journal of oncology. 2013;1(6):48-55. (In Russ.)